Latest information on COVID-19
Support teaching, research, and patient care.
David A. Stevenson, MD is a physician board certified in both pediatrics and medical genetics. He completed his pediatric residency at the University of New Mexico and completed his medical genetics residency at the University of Utah. Dr. Stevenson is the program director for the Combined Pediatric-Medical Genetics Residency Program and the Medical Genetics Residency Program at Stanford. He is actively involved in graduate medical education and developing innovative ways of training the next generation of medical geneticists. In addition, as co-director of the Genetic Testing Optimization Service, he focuses on researching best practices for genetic testing utilization. Dr. Stevenson sees all types of individuals with various genetic disorders in his clinical practice. However, he has particular interests in disorders of the Ras/MAPK pathway which includes neurofibromatosis type 1, Noonan syndrome, CFC syndrome, and Costello syndrome. He also has expertise in evaluating individuals with vascular anomalies including hereditary hemorrhagic telangiectasia, and skeletal dysplasias. Dr. Stevenson is on the scientific advisory board for Prader-Willi Syndrome Association (PWSA) and has a focus on treating individuals with Prader-Willi syndrome. He has research interests in identifying clinical trial endpoints and is actively involved in clinical trials.Dr. Stevenson is a section editor for "Genetics in Medicine", and a member of the ACMG Board of Directors.
My research focuses on disorders of the RAS/MAPK pathway (e.g. NF1, Noonan, CFC, and Costello syndrome). I am working on understanding the impact of RAS signaling on the musculoskeletal system. Through multi-disciplinary collaborations I am utilizing genomic approaches to identify somatic events and modifiers in the RASopathies. I am also involved in identifying outcome measures for use in clinical trials for the associated orthopedic manifestations. Other areas of research involve vascular anomalies, Prader-Willi syndrome, and hypophosphatasia.
A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
The purpose of this is study is to evaluate the effects of DCCR (diazoxide choline controlled
release tablets) in children and adults with Prader-Willi syndrome.
View full details